Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

PHILADELPHIA, July 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
July 21, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
July 19, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Key Executive Appointments

PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central...
June 01, 2021 07:00 ET | Source: Passage Bio

Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio

PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
May 26, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming June Investor Conferences

PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central...
May 11, 2021 06:30 ET | Source: Passage Bio

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Passage Bio collaborator University of Pennsylvania’s Gene Therapy Program to present poster regarding development of a novel mouse model for evaluating efficacy of adeno-associated virus gene therapy...
May 10, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Host Virtual R&D Event on May 17

PHILADELPHIA, May 10, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central...
May 05, 2021 07:00 ET | Source: Passage Bio

Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights

Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker data expected 4Q21Received multiple regulatory clearances for clinical...
May 03, 2021 07:00 ET | Source: Passage Bio

Passage Bio Partners with InformedDNA® to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia

No-cost genetic screening and counseling program aimed at identifying FTD patients who have certain inherited genetic mutations to guide early treatment intervention and awareness of clinical...
April 29, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Report First Quarter 2021 Financial Results on May 5, 2021

PHILADELPHIA, April 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...